Obesity Paradox in Non Valvular Atrial Fibrillation Regarding Outcomes: Fact or Fiction
Overview
Obesity paradox In patient with non valvular atrial fibrillation
Full Title of Study: “Obesity Paradox in Non Valvular Atrial Fibrillation”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: August 1, 2023
Detailed Description
Study role of obesity in outcomes of anticoagulation in patients with non valvular atrial fibrillation
Interventions
- Drug: Oral Anticoagulant
- Oral tablets of anti coagulations either warfare or NOACs
Arms, Groups and Cohorts
- Obese Patients with non valvular AF
- Obese Patients with non valvular AF using oral anti coagulants
Clinical Trial Outcome Measures
Primary Measures
- Correlation between obesity and outcomes in non valvular atrial fibrillation
- Time Frame: Sixth months
- To study effect of obesity in outcomes of non valvular atrial fibrillation regarding the effect of obesity in the outcome of anticoagulants
Participating in This Clinical Trial
Inclusion Criteria
- patients presented with non valvular AF – patients on oral anticoagulant Exclusion Criteria:
- valvular AF – Mental illness – History of cerebrovascular stroke – history of bleeding tendency – history of Chronic renal failure
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Assiut University
- Provider of Information About this Clinical Study
- Principal Investigator: Christena amir, Principal investigator – Assiut University
- Overall Contact(s)
- Christen Henan, Ressident, 01201558854, Christenamir@yahoo.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.